Dr. Reddy's Laboratories Ltd.'s third quarter earnings have been generally staid, but a record number of generic launches in the US and management commentary of an overall uptrend alongside significant cost control measures could potentially enthuse investors.
Record Dr Reddy's US Launches In Q3 Set Tone For Earnings Pick Up?
Dr Reddy’s has had a record number of US launches in Q3 with potentially more in store and now a new US CEO to steer things through, improving outlook for a significant revival in earnings. But risks of delays and competition in certain key anticipated launches in 2019 could dull prospects.
